Trial Profile
A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms FOOTPATH
- 06 Jun 2023 Results of full analysis of efficacy and safety data presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 07 Sep 2022 Planned End Date changed from 1 Jun 2023 to 1 Jul 2023.
- 07 Sep 2022 Status changed from recruiting to active, no longer recruiting.